Antiarrhythmic effect of ischemic preconditioning during low-flow ischemia. The role of bradykinin and sarcolemmal versus mitochondrial ATP-sensitive K(+) channels

Basic Research in Cardiology
Sergey V DriamovC E Zaugg

Abstract

Short episodes of ischemia (ischemic preconditioning) protect the heart against ventricular arrhythmias during zero-flow ischemia and reperfusion. However, in clinics, many episodes of ischemia present a residual flow (low-flow ischemia). Here we examined whether ischemic preconditioning protects against ventricular arrhythmias during and after a low-flow ischemia and, if so, by what mechanism(s). Isolated rat hearts were subjected to 60 min of low-flow ischemia (12% residual coronary flow) followed by 60 min of reperfusion. Ischemic preconditioning was induced by two cycles of 5 min of zero-flow ischemia followed by 5 and 15 min of reperfusion, respectively. Arrhythmias were evaluated as numbers of ventricular premature beats (VPBs) as well as incidences of ventricular tachycardia (VT) and ventricular fibrillation (VF) during low-flow ischemia and reperfusion. Ischemic preconditioning significantly reduced the number of VPBs and the incidence of VT and of VF during low-flow ischemia. This antiarrhythmic effect of preconditioning was abolished by HOE 140 (100 nM), a bradykinin B(2) receptor blocker. Similar to preconditioning, exogenous bradykinin (10 nM) reduced the number of VPBs and the incidence of VT and of VF during low-f...Continue Reading

Citations

Jul 14, 2010·Cardiovascular Research·David A Brown, Brian O'Rourke
Apr 1, 2008·Journal of Cardiothoracic and Vascular Anesthesia·Leo G Kevin, Enis Novalija
Jan 19, 2007·Journal of Cardiovascular Electrophysiology·Sergey V DriamovChristian E Zaugg
Jan 24, 2007·Journal of Cardiovascular Electrophysiology·Barry London
Nov 27, 2007·European Journal of Pharmacology·Claudio ValentiCarlo Alberto Maggi
Apr 7, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Laura A HundahlThomas Jespersen
Feb 2, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Tetsuji MiuraToshiyuki Yano
Jan 8, 2010·Molecular and Cellular Biochemistry·Claudia WagnerChristof Weinbrenner
Apr 26, 2011·Pharmacology & Therapeutics·Fadi G Akar, Brian O'Rourke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.